olivLaw · US equity research
AbbVie Inc. ABBV
Pharmaceutical Preparations · SIC 2834 · Vertical: Pharmaceutical Preparations (SIC 2834)
AbbVie is a global, diversified research-based biopharmaceutical company with leadership positions in immunology, neuroscience, oncology and aesthetics. It reported worldwide net revenues of $61.2 billion in fiscal 2025, and $32.0 billion for the six months ended June 30, 2026, with reported growth of 11%. Its 2026 adjusted diluted EPS guidance including Q3 acquired IPR&D expense ranges from $13.76 to $13.96.
The AI analysis may be outdated: new filings came after its sources (see the «AI analysis» section).
At the close of 05 Nov 2026, AbbVie Inc. (ABBV) stock was 288.24 USD (−2.24% on the day), with market capitalisation 509.5 bn USD, P/E 49.6 on diluted EPS of 5.81 USD over the last 12 months, dividend yield 2.40%, beta 0.28, 52-week range 197.38–294.89 USD. Latest reported quarter (Q3 2026): revenue of 17.4 bn USD (+10.3% YoY), net income of 4.2 bn USD (+2,167.7% YoY), diluted EPS 2.37 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 57.0
- strong (55–70)
- Bollinger (20, 2)
- 275.94 – 295.50
- in the upper half of the band · %B 0.63 · band width 6.8%
- SMA 50 / 200
- 271.29 / 238.58
- uptrend (price > SMA50 > SMA200)
- MACD (12, 26, 9)
- 5.67 / 6.04
- MACD below signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | +8.1% | −5.9% | +14.0 pp | — |
| 3 months | +18.2% | −4.6% | +22.8 pp | — |
| 6 months | +42.2% | +0.2% | +42.0 pp | — |
| Year to date | +26.1% | +7.4% | +18.7 pp | — |
| 1 year | +33.0% | +8.2% | +24.8 pp | +25.1% |
| 3 years | +104.1% | +68.4% | +35.7 pp | +43.4% |
| 5 years | +146.0% | +56.5% | +89.4 pp | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q3 2026 · 30 Sept 2026
Quarterly margins
Quarterly statements · USD
| Fiscal year | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 15.1 bn | 13.3 bn | 15.4 bn | 15.8 bn | 16.6 bn | 15.0 bn | 17.0 bn | 17.4 bn |
| Cost of revenue | 4.4 bn | 4.0 bn | 4.3 bn | 5.3 bn | 4.6 bn | 4.2 bn | 4.3 bn | 4.3 bn |
| Gross profit | 10.7 bn | — | — | — | 12.1 bn | — | — | — |
| SG&A | 3.9 bn | 3.3 bn | 3.3 bn | 3.6 bn | 3.9 bn | 3.6 bn | 3.6 bn | 4.1 bn |
| Operating income | -1.5 bn | 3.7 bn | 4.9 bn | 1.9 bn | 4.5 bn | 4.0 bn | 6.4 bn | 6.3 bn |
| Interest expense | 702.0 m | 700.0 m | 740.0 m | 739.0 m | 714.0 m | 717.0 m | 746.0 m | 802.0 m |
| Pre-tax income | -2.3 bn | 1.7 bn | 1.6 bn | 714.0 m | 2.7 bn | 1.0 bn | 4.3 bn | 4.8 bn |
| Income tax | -2.2 bn | 372.0 m | 613.0 m | 526.0 m | 853.0 m | 342.0 m | 662.0 m | 609.0 m |
| Net income | -22.0 m | 1.3 bn | 938.0 m | 186.0 m | 1.8 bn | 695.0 m | 3.6 bn | 4.2 bn |
| Diluted EPS | -0.02 | 0.72 | 0.52 | 0.10 | 1.02 | 0.39 | 2.03 | 2.37 |
| Operating cash flow | 7.0 bn | 1.6 bn | 5.2 bn ≈ | 7.0 bn ≈ | 5.2 bn | 3.8 bn | 3.4 bn ≈ | 7.6 bn ≈ |
| Capex | 291.0 m | 235.0 m | 269.0 m ≈ | 381.0 m ≈ | 329.0 m | 265.0 m | 322.0 m ≈ | 301.0 m ≈ |
| Dividends paid | 2.8 bn | 2.9 bn | 2.9 bn ≈ | 2.9 bn ≈ | 2.9 bn | 3.1 bn | 3.1 bn ≈ | 3.1 bn ≈ |
| Share repurchases | 358.0 m | 961.0 m | 12.0 m ≈ | 4.0 m ≈ | 3.0 m | 1.5 bn | 9.0 m ≈ | 5.0 m ≈ |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Today's P/E sits at the 75 percentile of its own 44-quarter history (min 13.5, median 25.7, max 175.4; quarters with earnings only).
Fiscal years
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 32.8 bn | 33.3 bn | 45.8 bn | 56.2 bn | 58.1 bn | 54.3 bn | 56.3 bn | 61.2 bn |
| Revenue YoY | +16.1% | +1.6% | +37.7% | +22.7% | +3.3% | −6.4% | +3.7% | +8.6% |
| Net income | 5.7 bn | 7.9 bn | 4.6 bn | 11.5 bn | 11.8 bn | 4.9 bn | 4.3 bn | 4.2 bn |
| Net income YoY | +7.1% | +38.6% | −41.4% | +150.0% | +2.5% | −58.9% | −12.0% | −1.2% |
| Diluted EPS | 3.66 | 5.28 | 2.72 | 6.45 | 6.63 | 2.72 | 2.39 | 2.36 |
| Diluted EPS YoY | +10.9% | +44.3% | −48.5% | +137.1% | +2.8% | −59.0% | −12.1% | −1.3% |
| net % | 17.4% | 23.7% | 10.1% | 20.5% | 20.4% | 9.0% | 7.6% | 6.9% |
| Free cash flow | 12.8 bn | 12.8 bn | 16.8 bn | 22.0 bn | 24.2 bn | 22.1 bn | 17.8 bn | 17.8 bn |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 5.2 bn USD
- Financial debt
- 67.0 bn USD
- Net debt
- 61.8 bn USD
- Equity
- -3.2 bn USD
- Total assets
- 134.0 bn USD
- Debt / equity
- unavailable
- Current ratio
- 0.67x
- ROE
- unavailable
- ROA
- 3.1%
- FCF margin
- 29.1%
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Revenue | 45.8 bn | 56.2 bn | 58.1 bn | 54.3 bn | 56.3 bn | 61.2 bn | SEC (XBRL)· 20 Feb 2026verified |
| Cost of revenue | 15.4 bn | 17.4 bn | 17.4 bn | 20.4 bn | 16.9 bn | 18.2 bn | SEC (XBRL)· 20 Feb 2026verified |
| Gross profit | 30.4 bn ≈ | 38.8 bn ≈ | 40.6 bn ≈ | 33.9 bn ≈ | 39.4 bn ≈ | 43.0 bn ≈ | SEC (XBRL)· 20 Feb 2026derived |
| SG&A | 11.3 bn | 12.3 bn | 15.3 bn | 12.9 bn | 14.8 bn | 14.0 bn | SEC (XBRL)· 20 Feb 2026verified |
| Operating income | 11.4 bn | 17.9 bn | 18.1 bn | 12.8 bn | 9.1 bn | 15.1 bn | SEC (XBRL)· 20 Feb 2026verified |
| Interest expense | 2.5 bn | 2.4 bn | 2.2 bn | 2.2 bn | 2.8 bn | 2.9 bn | SEC (XBRL)· 20 Feb 2026verified |
| Pre-tax income | 3.4 bn | 13.0 bn | 13.5 bn | 6.3 bn | 3.7 bn | 6.6 bn | SEC (XBRL)· 20 Feb 2026verified |
| Income tax | -1.2 bn | 1.4 bn | 1.6 bn | 1.4 bn | -570.0 m | 2.4 bn | SEC (XBRL)· 20 Feb 2026verified |
| Net income | 4.6 bn | 11.5 bn | 11.8 bn | 4.9 bn | 4.3 bn | 4.2 bn | SEC (XBRL)· 20 Feb 2026verified |
| Diluted EPS | 2.72 | 6.45 | 6.63 | 2.72 | 2.39 | 2.36 | SEC (XBRL)· 20 Feb 2026verified |
| Weighted average diluted shares | 1.7 bn | 1.8 bn | 1.8 bn | 1.8 bn | 1.8 bn | 1.8 bn | SEC (XBRL)· 20 Feb 2026verified |
| Dividend per share | 4.84 | 5.31 | 5.71 | 5.99 | 6.29 | 6.65 | SEC (XBRL)· 20 Feb 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Revenue − Cost of revenue.
Balance sheet · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 8.4 bn | 9.7 bn | 9.2 bn | 12.8 bn | 5.5 bn | 5.2 bn | SEC (XBRL)· 20 Feb 2026verified |
| Receivables | 8.8 bn | 10.0 bn | 11.3 bn | 11.2 bn | 10.9 bn | 12.6 bn | SEC (XBRL)· 20 Feb 2026verified |
| Inventories | 3.3 bn | 3.1 bn | 3.6 bn | 4.1 bn | 4.2 bn | 5.0 bn | SEC (XBRL)· 20 Feb 2026verified |
| Current assets | 24.2 bn | 27.9 bn | 28.5 bn | 33.0 bn | 25.6 bn | 29.1 bn | SEC (XBRL)· 20 Feb 2026verified |
| Property, plant & equipment, net | 5.2 bn | 5.1 bn | 4.9 bn | 5.0 bn | 5.1 bn | 5.6 bn | SEC (XBRL)· 20 Feb 2026verified |
| Goodwill | 33.1 bn | 32.4 bn | 32.2 bn | 32.3 bn | 35.0 bn | 35.6 bn | SEC (XBRL)· 20 Feb 2026verified |
| Intangibles (excl. goodwill) | 82.9 bn | 76.0 bn | 67.4 bn | 55.6 bn | 60.1 bn | 52.6 bn | SEC (XBRL)· 20 Feb 2026verified |
| Total assets | 150.6 bn | 146.5 bn | 138.8 bn | 134.7 bn | 135.2 bn | 134.0 bn | SEC (XBRL)· 20 Feb 2026verified |
| Accounts payable | 2.3 bn | 2.9 bn | 2.9 bn | 3.7 bn | 2.9 bn | 3.6 bn | SEC (XBRL)· 20 Feb 2026verified |
| Short-term debt | 34.0 m | 14.0 m | 1.0 m | 0 | 0 | 2.5 bn | SEC (XBRL)· 20 Feb 2026verified |
| Long-term debt | 84.9 bn | 76.0 bn | 63.1 bn | 59.2 bn | 66.8 bn | 64.5 bn | SEC (XBRL)· 20 Feb 2026verified |
| Current liabilities | 28.7 bn | 35.2 bn | 29.5 bn | 37.8 bn | 38.7 bn | 43.3 bn | SEC (XBRL)· 20 Feb 2026verified |
| Equity | 13.1 bn | 15.4 bn | 17.3 bn | 10.4 bn | 3.4 bn | -3.2 bn | SEC (XBRL)· 20 Feb 2026verified |
Cash flow · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | 17.6 bn | 22.8 bn | 24.9 bn | 22.8 bn | 18.8 bn | 19.0 bn | SEC (XBRL)· 20 Feb 2026verified |
| Capex | 798.0 m | 787.0 m | 695.0 m | 777.0 m | 974.0 m | 1.2 bn | SEC (XBRL)· 20 Feb 2026verified |
| Free cash flow | 16.8 bn ≈ | 22.0 bn ≈ | 24.2 bn ≈ | 22.1 bn ≈ | 17.8 bn ≈ | 17.8 bn ≈ | SEC (XBRL)· 20 Feb 2026derived |
| Investing cash flow | -37.6 bn | -2.3 bn | -623.0 m | -2.0 bn | -20.8 bn | -6.6 bn | SEC (XBRL)· 20 Feb 2026verified |
| Financing cash flow | -11.5 bn | -19.0 bn | -24.8 bn | -17.2 bn | -5.2 bn | -12.7 bn | SEC (XBRL)· 20 Feb 2026verified |
| Dividends paid | 7.7 bn | 9.3 bn | 10.0 bn | 10.5 bn | 11.0 bn | 11.7 bn | SEC (XBRL)· 20 Feb 2026verified |
| Share repurchases | 978.0 m | 934.0 m | 1.5 bn | 2.0 bn | 1.7 bn | 980.0 m | SEC (XBRL)· 20 Feb 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
Score: 40 / 100
A scoring methodology on indicators and valuation, not investment advice.
Closing price
05 Nov 2026Source: olivLaw, closing series
Market cap: 509.5 bn USD
Key indicators
Coverage and freshness
Score by group
- Quality72
- Growth7
- Balance sheet54
- Returns55
- Valuation33
Estimated value range
The combined range = the median of the valid methods' low, central and high values; it is not a probability interval and does not cover every result. Envelope of all methods: 87.39 – 246.42 USD.
Valuation assumptions are editorial choices, not measured; beta is not measured.
Method ranges (USD per share)
— — Mid · ▏ Price
Valuation methods
- DCF (discounted cash flow)154.63 – 230.98 (Mid 184.45)WACC 9.3% · starting FCFF 21.3 bn USD · terminal value share of EV 72%The WACC × g sensitivity gives the method's bounds; these are not probabilities.Reverse DCF: starting growth implied by the price (fading linearly to terminal growth, everything else fixed): 23.1%
- Peers: EV/EBITDAunavailable · input data missing
- Peers: P/E159.36 – 246.42 (Mid 239.94)7 companies used · median multiple 41.3x · quartiles 27.4x – 42.4xABT, BMY, JNJ, LLY, PFE, REGN, VRTX
- Dividend discount (DDM)87.39 – 117.52 (Mid 100.24)
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Neutral profile · Score 40/100
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | unavailable | unavailable | — |
| Net margin · Quality | 15.7% | 44 (vs peers) | 9% |
| FCF conversion · Quality | 182.5% | 100 (on a fixed band) | 9% |
| Revenue CAGR 3Y · Growth | 1.8% | 15 (on a fixed band) | 12% |
| EPS CAGR 3Y · Growth | -29.1% | 0 (on a fixed band) | 12% |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | 7.1x | 87 (on a fixed band) | 9% |
| Current ratio · Balance sheet | 0.9x | 6 (on a fixed band) | 6% |
| P/E (TTM) · Valuation | 49.6x | 22 (vs peers) | 15% |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | 3.7% | 46 (on a fixed band) | 12% |
| Shareholder yield (distributions) · Returns | 2.7% | 38 (on a fixed band) | 9% |
| Payout ratio (FCF) · Returns | 64.3% | 80 (on a fixed band) | 6% |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet54/100 · 2/3 factors with a value
- Growth7/100 · 2/2 factors with a value
- Quality72/100 · 2/3 factors with a value
- Returns55/100 · 2/2 factors with a value
- Valuation33/100 · 2/3 factors with a value
Memo
AbbVie Inc. (ABBV). Latest full fiscal year: 2025; data up to 2026-09-30.
Figures computed from the financial statements: revenue 61.2 bn USD in 2025; YoY growth 8.6%; net margin 15.7%.
The estimated value range is 154.63–230.98 USD per share (median of 3 methods, agreement: low); assumptions are illustrative. Against the central value of 184.45 USD, the price of 288.24 USD leaves a potential of -36.0% (value / price − 1) and a margin of safety of -56.3% (1 − price / value). The range is the median of the methods' low, central and high values, not a probability interval.
olivLaw score 40/100, methodological classification: neutral profile (score, margin of safety and method agreement together; not a judgement of the right price). Not investment advice.
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- FCF conversion: 182.5%
- Interest coverage: 7.1x
- Payout ratio (FCF): 64.3%
What contradicts it
- Revenue CAGR 3Y: 1.8%
- EPS CAGR 3Y: -29.1%
- Current ratio: 0.9x
- P/E (TTM): 49.6x
- The price is above the estimated value range
- The valuation methods diverge
Not assessed (insufficient data or a ratio without meaning): ROIC, Net debt / EBITDA, EV/EBITDA.
Versus the vertical median
Pharmaceutical Preparations (SIC 2834) · same industry (4-digit SIC) · compared with 9 companies
Only companies with a capitalisation between 63.0 bn and 4,031.7 bn (within 8× of the company's); 367 of the vertical were left out.
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| LLYEli Lilly And Company | 1,283.9 bn | 44.3 | 86.1% | 31.9% | +44.7% | +27% / +131% |
| JNJJohnson & Johnson | 655.6 bn | 41.3 | 20.0% | 16.2% | +6.0% | +32% / +76% |
| ONCBeone Medicines Ltd. | 575.0 bn | 640.9 | 18.4% | 13.9% | +40.2% | +14% / +107% |
| ABBVAbbVie Inc. | 509.5 bn | 49.6 | — | 15.7% | +8.6% | +33% / +104% |
| MRKMerck & Co., Inc. | 362.2 bn | 151.2 | 5.1% | 3.6% | +1.3% | +40% / +43% |
| ABTAbbott Laboratories | 196.7 bn | 42.3 | 9.2% | 9.7% | +5.7% | −12% / +9% |
| PFEPfizer Inc | 170.3 bn | 42.6 | 4.4% | 6.3% | −1.6% | +16% / −2% |
| VRTXVertex Pharmaceuticals Inc | 137.5 bn | 34.9 | 20.8% | 30.7% | +8.9% | +25% / +53% |
| BMYBristol-Myers Squibb Company | 129.0 bn | 14.0 | 44.1% | 18.5% | −0.2% | +28% / +28% |
| REGNRegeneron Pharmaceuticals, Inc. | — | 19.9 | 14.9% | 28.5% | +1.0% | +16% / +10% |
1- and 3-year price returns: for ABBV from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (USD)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | 166.83 Total return -41% · Per year -41% | 295.35 Total return 5% · Per year 5% | 445.43 Total return 57% · Per year 57% |
| 3 years | 153.10 Total return -42% · Per year -17% | 305.79 Total return 12% · Per year 4% | 507.62 Total return 84% · Per year 23% |
| 5 years | 140.49 Total return -44% · Per year -11% | 316.61 Total return 21% · Per year 4% | 578.49 Total return 115% · Per year 17% |
- Exit P/E± 76.45
- Net margin± 53.51
- Annual revenue growth± 45.12
- Annual dilution± 4.50
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 05 Oct 2026; since then the company filed 10-Q (03 Nov 2026), 8-K (30 Oct 2026 · results).
In brief
AbbVie is a global, diversified research-based biopharmaceutical company with leadership positions in immunology, neuroscience, oncology and aesthetics. It reported worldwide net revenues of $61.2 billion in fiscal 2025 1, and $32.0 billion for the six months ended June 30, 2026, with reported growth of 11% 2. Its 2026 adjusted diluted EPS guidance including Q3 acquired IPR&D expense ranges from $13.76 to $13.96 3.
SWOT
Strengths
- The diversified portfolio, with leading positions in several therapeutic areas, reduces dependence on any single product 1.
- The company generates solid operating cash flows that support research and dividend payments 12.
- International commercial infrastructure and an extensive pipeline allow repeated launches and indication expansions 2.
Weaknesses
- Revenue concentration in a few products, particularly Skyrizi and Rinvoq, exposes the company to specific risks 1.
- Amortization of intangible assets and changes in contingent consideration liabilities affect reported results 12.
- Some major pipeline studies have not met their primary endpoints, showing the high risk of development 2.
Opportunities
Risks
- Dependence on Skyrizi and Rinvoqhigh
The two products represent a significant part of revenues, so market or patent problems would have an important effect on results 1.
- Loss of patent protectionhigh
Patent challenges or earlier-than-expected expiry could reduce revenues and operating earnings 1.
- Government pricing pressurehigh
Mechanisms under the Inflation Reduction Act and other cost-containment initiatives could reduce revenues, and new products could be selected in later years 1.
- Research and development failuremedium
Many pipeline programs do not reach the market, and some major studies have missed their primary endpoints, which could affect long-term growth 12.
- Acquisition and integration costsmedium
Amortization of intangible assets and changes in contingent consideration liabilities can strongly influence reported results across periods 12.
Investment thesis
What would need to be true (bull case)
- If Skyrizi, Rinvoq and new indications continue to grow, the company could sustain revenue growth supported by a diversified portfolio 12.
- The agreement with the U.S. government and manufacturing investments could reduce uncertainty over tariffs and pricing for a period 12.
- A pipeline of around 90 programs, many in advanced stages, could generate new revenue sources if many reach approval 2.
What would break the thesis
- If government price pressure extends to more major products, revenues could decline faster than expected 1.
- Early generic or biosimilar entry could reduce sales of major products before the estimated end of protection 1.
- Clinical trial failures and high pipeline costs could limit long-term profit growth 2.
What to watch
- Quarterly results and updated adjusted EPS guidanceQ3 2026
- FDA decision on subcutaneous Skyrizi in Crohn's disease and new Rinvoq indications2026
- Implementation of the U.S. government agreement and effects on Medicaid prices2027
- Evolution of Medicare government-set prices for Vraylar, Linzess and Botox2027 / 2028
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 05 Oct 2026; since then the company filed 10-Q (03 Nov 2026), 8-K (30 Oct 2026 · results).
The business
AbbVie Inc. was incorporated in Delaware in 2012 and became independent of Abbott Laboratories on January 1, 2013, when Abbott distributed all of AbbVie's common stock to its shareholders 1. The company develops, manufactures and sells innovative medicines and operates as a single global business segment 1. Its portfolio spans immunology, neuroscience, oncology, aesthetics and eye care, with leading products such as Skyrizi, Rinvoq and Botox 1.
AbbVie Inc. was incorporated in Delaware in 2012 and became independent of Abbott Laboratories on January 1, 2013, when Abbott distributed all of AbbVie's common stock to its shareholders 1. The company develops, manufactures and sells innovative medicines and operates as a single global business segment 1. Its portfolio spans immunology, neuroscience, oncology, aesthetics and eye care, with leading products such as Skyrizi, Rinvoq and Botox 1.
On research, the company maintains a pipeline of approximately 90 compounds, devices or indications, of which approximately 60 are in mid- and late-stage development 2. In the United States products are distributed mainly through independent wholesale distributors, and outside the United States mainly through wholesalers, distributors and national payer systems 1. Sales are concentrated among a few customers, but the company states that losing any single customer would not have a material adverse effect 1.
The 2026 strategy aims to maximize growth of key on-market products, deliver recent launches and acquisitions, and generate cash flow for research and dividends 12. The company has also announced U.S. manufacturing investments, including a pharmaceutical campus in North Carolina and new facilities in Illinois 2.
Segments
Immunology
Skyrizi and Rinvoq together accounted for approximately 42% of total net revenues in 2025, each exceeding the 10% threshold 1. In 2026 Rinvoq received new approvals and filings for vitiligo and alopecia areata 2.
Market context
The pharmaceutical market in which AbbVie operates is strongly shaped by pricing pressure, including through the Inflation Reduction Act, which introduced government-set prices for certain medicines 1. Competition from generics and biosimilars for products whose patents expire is also relevant 1.
In January 2026 the company entered a voluntary agreement with the U.S. government providing lower Medicaid prices and a three-year exemption from tariffs and future price mandates 12. The long-term impact of these measures remains uncertain and could reshape market conditions 1.
Trends
- Pricing and regulatory policymixed
Government price-setting under the Inflation Reduction Act and international reference pricing ideas could reduce revenues of selected products, while the voluntary agreement with the government provides a period of stability 1.
- Patent expiry and biosimilarsheadwind
Competition from biosimilars and generics could reduce sales of biologics once protection expires, although for Rinvoq no generic entry is expected in the United States before April 2037, subject to conditions 1.
- U.S. manufacturing investmenttailwind
Announced investments in U.S. plants and research could support production capacity and government relations, but involve large capital spending 12.
- New indications and approvalstailwind
Recent approvals and filings for Skyrizi, Rinvoq, Qulipta and Venclexta extend the market for existing products, if clinical results and approvals are confirmed 2.
Competitive position
The company operates in a competitive market where generic and biosimilar makers, as well as large pharmaceutical companies developing biosimilars, could reduce its market share 1. Competition also comes from innovations by other companies that could make existing products less attractive 1.
In immunology and neuroscience, competitors are other companies developing similar therapies, while in oncology and eye care competition is equally intense 1. The analyzed sources do not confirm exact market positions against each competitor 1.
- Large pharmaceutical companies with biosimilars
Companies expanding into biotechnology and forming biosimilar partnerships are named among the company's risks 1.
- Generic drug manufacturers
Generic makers file applications for generic versions of AbbVie products before patent expiry 1.
- Biotechnology companies with similar therapies
Other companies develop products that could compete with AbbVie's pipeline therapies 1.
- Genmab A/S
Genmab collaborates on the development of Epkinly but could become a competitor in some lymphoma indications 1.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
- Pharma's next cash cows could be specialized treatmentsAxios · 02 Nov 2026 · EN
- Advancing the Conversation on Ovarian CancerBudapest Business Journal (HU, EN) · 02 Nov 2026 · EN
- Povorcitinib for nonsegmental vitiligo: two randomized, controlled, phase 3 STOP-V trialsNature Medicine · 02 Nov 2026 · EN
- Neoadjuvant botensilimab with or without balstilimab in pMMR and dMMR colon cancer: the phase 2 UNICORN trialNature Medicine · 02 Nov 2026 · EN
- Rezumatul zilei: Prăbușirea sectorului tehnologic pe Wall Street și un atac istoric asupra Binance - XTB.comSurge — Google News · 30 Oct 2026 · RO
- 5-year outcomes of chemotherapy de-escalation in HER2-positive early breast cancer and exploratory circulating tumor DNA analyses from the randomized phase 2 PHERGain trialNature Medicine · 29 Oct 2026 · EN
- Insights into early-onset colorectal cancer from a single-nucleus RNA-seq atlas of colorectal cancer across the age continuumNature Medicine · 29 Oct 2026 · EN
- Birth weight, cognitive reserve and outcomes after first-episode psychosisNature Mental Health · 28 Oct 2026 · EN
- I just bought this pharma stock for its next generation of blockbuster drugs — and its dividendCNBC — Top News · 27 Oct 2026 · EN
- Metabolic heterogeneity of obesityNature Medicine · 27 Oct 2026 · EN
- Why pharma firms are betting billions on psychedelic drugs despite setbacksNature · 27 Oct 2026 · EN
- Neoadjuvant durvalumab plus chemotherapy in resectable or borderline resectable non-small-cell lung cancer: the phase 2 MDT-BRIDGE trialNature Medicine · 26 Oct 2026 · EN
- STAT+: Pharmalittle: We’re reading about a cancer vaccine, an experimental pancreatic cancer drug, and moreSTAT News · 23 Oct 2026 · EN
- Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic cancer: the randomized phase 2 AMPLIFY-7P trialNature Medicine · 23 Oct 2026 · EN
- STAT+: AbbVie skin disorder drug succeeds in late-stage trial, but results miss market expectationsSTAT News · 22 Oct 2026 · EN
- Real-world, digital-first delivery of GLP-1 receptor agonist therapy in womenNature Medicine · 16 Oct 2026 · EN
- Big pharma stocks near all-time highs as tech selloff pushes investors toward safer betsMarketWatch — Top Stories · 15 Oct 2026 · EN
- Personalized neoantigen-targeting cancer vaccines in ovarian cancer: a phase 1 trialNature Medicine · 14 Oct 2026 · EN
- Autologous and broadly neutralizing antibodies drive ART-free HIV controlNature Medicine · 13 Oct 2026 · EN
- Рынки акций Европы выросли во вторникInterfax Russia (RU) · 07 Oct 2026 · RU
The latest news item in our archive is from 02 Nov 2026; the newest SEC filing is from 03 Nov 2026. The press archive comes from the RSS feeds we follow and does not necessarily cover the latest event — the filings alongside do.
SEC filings
- Quarterly report03 Nov 2026
- Current report02 Nov 2026Departure or appointment of officers
- Current report30 Oct 2026Results of operations · Financial statements and exhibits
- Current report15 Oct 2026Departure or appointment of officers
- Current report05 Oct 2026Results of operations · Financial statements and exhibits
- Current report03 Sept 2026Regulation FD disclosure · Financial statements and exhibits
- Current report18 Aug 2026Other events · Financial statements and exhibits
- Current report05 Aug 2026Other events · Financial statements and exhibits
- Quarterly report03 Aug 2026
- Current report31 Jul 2026Results of operations · Financial statements and exhibits
Sources
- [1] Form 10-K, fiscal year ended 2025-12-31 · SEC / AbbVie Inc. · 20 Feb 2026
- [2] Form 10-Q, quarter ended 2026-06-30 · SEC / AbbVie Inc. · 03 Aug 2026
- [3] Form 8-K, results release (exhibit 99.1) · SEC / AbbVie Inc. · 05 Oct 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.